Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
Authors
Duffy, Michael Jvan Rossum, Leo G M
van Turenhout, Sietze T
Malminiemi, Outi
Sturgeon, Catherine
Lamerz, Rolf
Nicolini, Andrea
Haglund, Caj
Holubec, Lubos
Fraser, Callum G
Halloran, Stephen P
Affiliation
Department of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin and UCD School of Medicine and Medical Science, University, College Dublin, Dublin, Ireland. Michael.J.Duffy@ucd.ieIssue Date
2012-02-01T10:29:20ZMeSH
Colorectal Neoplasms/diagnosis/genetics/*metabolismDNA, Neoplasm/analysis
Europe
Feces/*chemistry
Humans
Mass Screening/*methods
Occult Blood
Predictive Value of Tests
Reproducibility of Results
Tumor Markers, Biological/*analysis
Metadata
Show full item recordCitation
Int J Cancer. 2011 Jan 1;128(1):3-11. doi: 10.1002/ijc.25654.Journal
International journal of cancer. Journal international du cancerDOI
10.1002/ijc.25654PubMed ID
20824704Abstract
Several randomized controlled trials have shown that population-based screening using faecal occult blood testing (FOBT) can reduce mortality from colorectal neoplasia. Based on this evidence, a number of countries have introduced screening for colorectal cancer (CRC) and high-risk adenoma and many others are considering its introduction. The aim of this article is to critically review the current status of faecal markers as population-based screening tests for these neoplasia. Most of the available faecal tests involve the measurement of either occult blood or a panel of DNA markers. Occult blood may be measured using either the guaiac faecal occult blood test (gFOBT) or a faecal immunochemical test (iFOBT). Although iFOBT may require a greater initial investment, they have several advantages over gFOBT, including greater analytical sensitivity and specificity. Their use results in improved clinical performance and higher uptake rates. Importantly for population screening, some of the iFOBTs can be automated and provide an adjustable cutoff for faecal haemoglobin concentration. However, samples for iFOBT, may be less stable after collection than for gFOBT. For new centres undertaking FOBT for colorectal neoplasia, the European Group on Tumour Markers recommends use of a quantitative iFOBT with an adjustable cutoff point and high throughput analysis. All participants with positive FOBT results should be offered colonoscopy. The panel recommends further research into increasing the stability of iFOBT and the development of improved and affordable DNA and proteomic-based tests, which reduce current false negative rates, simplify sample transport and enable automated analysis.Language
engISSN
1097-0215 (Electronic)0020-7136 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1002/ijc.25654
Scopus Count
Collections
Related articles
- Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
- Authors: Medical Advisory Secretariat
- Issue date: 2009
- Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
- Authors: Tinmouth J, Lansdorp-Vogelaar I, Allison JE
- Issue date: 2015 Aug
- Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
- Authors: Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, Tichet J, Launoy G
- Issue date: 2007 Feb
- Immunochemical faecal occult blood tests have superior stability and analytical performance characteristics over guaiac-based tests in a controlled in vitro study.
- Authors: Lee CS, O'Gorman P, Walsh P, Qasim A, McNamara D, O'Morain CA, Boran GP
- Issue date: 2011 Jun